SMAD3 and idiopathic pulmonary fibrosis: In order to determine whether PM014 is capable of exerting anti-fibrotic effects on fibroblast cells, we assessed activation of p38 MAPK as well as Smad2 and Smad3 in lung fibroblasts from healthy donor and IPF patients (Fig. S5).